patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_665498 | REC_0015501 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.3 | 71 | female | 2 | 10 | 6.5 | 6 | sotorasib 960 mg daily | 11 | true | MSS | 2026-03-15T05:36:01.288394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367661 | REC_0015502 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.6 | 66 | male | 1 | 21 | 4.7 | 5 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:36:01.290630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317818 | REC_0015503 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.2 | 79 | female | 1 | 24 | 5.9 | 4 | pembrolizumab 200 mg q3w | 8.4 | true | MSS | 2026-03-15T05:36:01.291132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618467 | REC_0015504 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.1 | 57 | male | 0 | 18 | 7.2 | 4 | sotorasib 960 mg daily | 8.1 | true | MSS | 2026-03-15T05:36:01.291581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168580 | REC_0015505 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 18.4 | 73 | male | 0 | 16 | 5.8 | 1 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:01.292024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623888 | REC_0015506 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.3 | 73 | female | 0 | 16 | 6 | 6 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:01.292548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344310 | REC_0015507 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 16 | 54 | male | 0 | 9 | 6.5 | 5 | sotorasib 960 mg daily | 18.7 | false | MSS | 2026-03-15T05:36:01.292931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239338 | REC_0015508 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 13.8 | 70 | female | 1 | 18 | 4.5 | 2 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:01.293279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558565 | REC_0015509 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8 | 79 | female | 0 | 28 | 6.2 | 6 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:01.293613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675724 | REC_0015510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.1 | 72 | female | 2 | 3 | 2.8 | 8 | osimertinib 80 mg daily | 15 | true | MSI-H | 2026-03-15T05:36:01.294154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328243 | REC_0015511 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 10 | 59 | female | 0 | 21 | 5.1 | 2 | alectinib 600 mg BID | 17 | false | MSS | 2026-03-15T05:36:01.294543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151390 | REC_0015512 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.7 | 76 | female | 2 | 4 | 5.3 | 4 | alectinib 600 mg BID | 6.1 | true | MSS | 2026-03-15T05:36:01.294857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236973 | REC_0015513 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 13.3 | 73 | female | 1 | 20 | 5.6 | 4 | sotorasib 960 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:36:01.295180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421215 | REC_0015514 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.4 | 58 | female | 0 | 17 | 4.9 | 1 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:36:01.295490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158692 | REC_0015515 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 13 | 10.2 | 66 | female | 1 | 15 | 8.2 | 3 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:36:01.295796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782013 | REC_0015516 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 4.5 | 73 | male | 1 | 14 | 5.2 | 0 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:01.296167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144901 | REC_0015517 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.3 | 53 | female | 0 | 21 | 6.6 | 3 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:36:01.296512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611711 | REC_0015518 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 4 | 72 | female | 2 | 43 | 7.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:36:01.296867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480769 | REC_0015519 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17 | 50 | female | 0 | 16 | 7.3 | 6 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:36:01.297253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679647 | REC_0015520 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 15.1 | 67 | female | 0 | 15 | 5.6 | 1 | entrectinib 600 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:36:01.297639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925658 | REC_0015521 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.8 | 74 | male | 2 | 22 | 5.6 | 1 | pembrolizumab 200 mg q3w | 24.4 | false | MSS | 2026-03-15T05:36:01.300337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679648 | REC_0015522 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.1 | 67 | male | 1 | 7 | 6.2 | 6 | sotorasib 960 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:36:01.300945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715157 | REC_0015523 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.3 | 76 | female | 2 | 12 | 3.6 | 6 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:36:01.302231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732872 | REC_0015524 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 8.8 | 63 | female | 0 | 5 | 5.1 | 0 | osimertinib 80 mg daily | 20.4 | false | MSS | 2026-03-15T05:36:01.302724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409337 | REC_0015525 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 9.2 | 64 | male | 0 | 10 | 5.3 | 0 | osimertinib 80 mg daily | 28.4 | true | MSS | 2026-03-15T05:36:01.303171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589463 | REC_0015526 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.4 | 60 | male | 0 | 11 | 4.5 | 1 | alectinib 600 mg BID | 22.1 | true | MSS | 2026-03-15T05:36:01.303590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359544 | REC_0015527 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.1 | 60 | male | 0 | 32 | 5.9 | 5 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:36:01.304646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491704 | REC_0015528 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16 | 51 | female | 0 | 12 | 6.5 | 5 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:01.305282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277780 | REC_0015529 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6 | 65 | female | 0 | 9 | 7 | 6 | pembrolizumab 200 mg q3w | 16.2 | true | MSS | 2026-03-15T05:36:01.306734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358119 | REC_0015530 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.8 | 73 | female | 1 | 13 | 6.1 | 7 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:36:01.307260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991674 | REC_0015531 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.6 | 64 | female | 0 | 14 | 5.5 | 1 | entrectinib 600 mg daily | 18.4 | true | MSS | 2026-03-15T05:36:01.307658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532158 | REC_0015532 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.5 | 66 | female | 0 | 16 | 4.9 | 1 | pembrolizumab 200 mg q3w | 6.4 | true | MSS | 2026-03-15T05:36:01.308050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105420 | REC_0015533 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 4.9 | 78 | female | 1 | 7 | 4.7 | 3 | osimertinib 80 mg daily | 4.5 | false | MSS | 2026-03-15T05:36:01.308537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730590 | REC_0015534 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7 | 84 | female | 2 | 111 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:36:01.308932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315388 | REC_0015535 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 5.8 | 53 | female | 0 | 18 | 5.4 | 3 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:36:01.309329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944678 | REC_0015536 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13.4 | 71 | male | 1 | 20 | 6.6 | 2 | pembrolizumab 200 mg q3w | 29.6 | true | MSI-H | 2026-03-15T05:36:01.309902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433908 | REC_0015537 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8.7 | 75 | female | 2 | 25 | 5.6 | 6 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:36:01.310362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350201 | REC_0015538 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 12 | 50 | female | 0 | 2 | 7.1 | 7 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:01.310802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798839 | REC_0015539 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 13 | 69 | male | 1 | 9 | 8.4 | 0 | sotorasib 960 mg daily | 35.4 | false | MSI-H | 2026-03-15T05:36:01.311204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190030 | REC_0015540 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 20.2 | 79 | female | 2 | 12 | 6.7 | 4 | osimertinib 80 mg daily | 4.7 | false | MSI-H | 2026-03-15T05:36:01.311595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738255 | REC_0015541 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 16.6 | 57 | female | 1 | 11 | 5.4 | 3 | pembrolizumab 200 mg q3w | 21.4 | false | MSI-H | 2026-03-15T05:36:01.311997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857056 | REC_0015542 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 16 | 17.2 | 56 | female | 1 | 6 | 6.9 | 0 | sotorasib 960 mg daily | 49 | false | MSS | 2026-03-15T05:36:01.312487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532443 | REC_0015543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.2 | 76 | female | 2 | 21 | 3.6 | 7 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:36:01.312883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396386 | REC_0015544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.7 | 69 | female | 0 | 32 | 5.3 | 6 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:01.313280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423262 | REC_0015545 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 10 | 56 | male | 1 | 20 | 5.4 | 0 | entrectinib 600 mg daily | 39 | true | MSI-H | 2026-03-15T05:36:01.313652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421064 | REC_0015546 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 11.2 | 69 | female | 0 | 21 | 5.6 | 8 | osimertinib 80 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:01.314026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209340 | REC_0015547 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 16.8 | 62 | male | 1 | 16 | 6.1 | 3 | entrectinib 600 mg daily | 12 | false | MSI-H | 2026-03-15T05:36:01.314406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702278 | REC_0015548 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.1 | 69 | female | 0 | 21 | 5.8 | 7 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:36:01.317902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952572 | REC_0015549 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.9 | 66 | female | 1 | 35 | 5.8 | 1 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:36:01.318568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717853 | REC_0015550 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.9 | 67 | female | 1 | 19 | 6.1 | 5 | sotorasib 960 mg daily | 17 | false | MSS | 2026-03-15T05:36:01.318999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618069 | REC_0015551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.2 | 73 | female | 1 | 14 | 5.6 | 8 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:36:01.319373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663333 | REC_0015552 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 1.5 | 70 | female | 0 | 71 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:36:01.319727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790561 | REC_0015553 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 7.3 | 71 | female | 0 | 13 | 4.5 | 6 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:01.320192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272123 | REC_0015554 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11.8 | 66 | female | 1 | 14 | 5.2 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSI-H | 2026-03-15T05:36:01.320672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277070 | REC_0015555 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 13.3 | 79 | female | 1 | 19 | 5.7 | 6 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:01.321092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245219 | REC_0015556 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 10.2 | 63 | female | 0 | 73 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:36:01.321510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200884 | REC_0015557 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.8 | 73 | female | 2 | 8 | 4.3 | 6 | alectinib 600 mg BID | 11.5 | false | MSS | 2026-03-15T05:36:01.321930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536437 | REC_0015558 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.3 | 54 | female | 0 | 57 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:36:01.322335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862611 | REC_0015559 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 16.4 | 69 | female | 0 | 14 | 6.3 | 1 | entrectinib 600 mg daily | 16.9 | false | MSS | 2026-03-15T05:36:01.322709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598405 | REC_0015560 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 7.6 | 65 | male | 0 | 23 | 6.8 | 2 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:01.323095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637319 | REC_0015561 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.9 | 64 | female | 1 | 12 | 4.3 | 2 | entrectinib 600 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:36:01.323481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957843 | REC_0015562 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 4.9 | 63 | male | 0 | 15 | 5 | 4 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:01.323972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162113 | REC_0015563 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 15.8 | 64 | female | 1 | 15 | 6.4 | 7 | alectinib 600 mg BID | 12.8 | true | MSI-H | 2026-03-15T05:36:01.324437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768178 | REC_0015564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 5.8 | 72 | female | 1 | 18 | 5.9 | 3 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:01.324790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410896 | REC_0015565 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.2 | 59 | male | 1 | 37 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:36:01.325108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339534 | REC_0015566 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 12.2 | 69 | female | 0 | 16 | 5.6 | 0 | sotorasib 960 mg daily | 47.5 | true | MSI-H | 2026-03-15T05:36:01.325408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140768 | REC_0015567 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.7 | 67 | male | 1 | 16 | 5.2 | 5 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:36:01.325728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595422 | REC_0015568 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.8 | 58 | female | 1 | 62 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | true | MSS | 2026-03-15T05:36:01.326053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779075 | REC_0015569 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 6.4 | 69 | female | 1 | 19 | 4.1 | 2 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:36:01.326365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797803 | REC_0015570 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.1 | 65 | male | 0 | 30 | 8.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:36:01.326677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901056 | REC_0015571 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 4 | 71 | female | 2 | 0 | 5.5 | 1 | entrectinib 600 mg daily | 29.3 | false | MSS | 2026-03-15T05:36:01.326998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824777 | REC_0015572 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.9 | 61 | male | 1 | 20 | 4.8 | 6 | alectinib 600 mg BID | 12.9 | true | MSI-H | 2026-03-15T05:36:01.327352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740453 | REC_0015573 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 12.4 | 72 | male | 2 | 8 | 6.3 | 6 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:36:01.327740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540846 | REC_0015574 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.8 | 65 | male | 0 | 15 | 4.1 | 1 | osimertinib 80 mg daily | 21.1 | true | MSS | 2026-03-15T05:36:01.328207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192071 | REC_0015575 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.2 | 63 | male | 1 | 14 | 4.2 | 4 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:36:01.328840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375191 | REC_0015576 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.5 | 80 | female | 1 | 17 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:36:01.329296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127868 | REC_0015577 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 8.9 | 55 | male | 0 | 18 | 6.8 | 6 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:36:01.329711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108905 | REC_0015578 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.6 | 71 | male | 1 | 13 | 5.9 | 4 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:01.330133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172307 | REC_0015579 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.3 | 75 | female | 1 | 16 | 5.5 | 4 | sotorasib 960 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:36:01.330540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683722 | REC_0015580 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4 | 67 | female | 1 | 51 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.330941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850305 | REC_0015581 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 8.4 | 63 | male | 1 | 10 | 4 | 1 | pembrolizumab 200 mg q3w | 29.2 | true | MSS | 2026-03-15T05:36:01.331379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535403 | REC_0015582 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.3 | 67 | male | 0 | 16 | 5.1 | 6 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:01.332046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996133 | REC_0015583 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 7.6 | 80 | male | 2 | 20 | 6.5 | 2 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:36:01.332562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192530 | REC_0015584 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11 | 75 | female | 0 | 15 | 6.6 | 6 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:36:01.332967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895199 | REC_0015585 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 13.8 | 65 | female | 0 | 15 | 5.5 | 0 | osimertinib 80 mg daily | 42.6 | true | MSS | 2026-03-15T05:36:01.333347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388905 | REC_0015586 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 14.2 | 70 | female | 2 | 10 | 4.6 | 2 | entrectinib 600 mg daily | 24.4 | true | MSS | 2026-03-15T05:36:01.333693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335118 | REC_0015587 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 17.8 | 69 | female | 1 | 22 | 4.3 | 1 | sotorasib 960 mg daily | 19.2 | false | MSS | 2026-03-15T05:36:01.334078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705326 | REC_0015588 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 9.5 | 67 | female | 1 | 22 | 4.6 | 2 | pembrolizumab 200 mg q3w | 24.6 | false | MSS | 2026-03-15T05:36:01.334708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922006 | REC_0015589 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.8 | 68 | female | 1 | 15 | 4.3 | 2 | sotorasib 960 mg daily | 29.8 | true | MSS | 2026-03-15T05:36:01.335158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151949 | REC_0015590 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 20.2 | 66 | female | 0 | 17 | 5.4 | 6 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:01.335549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888196 | REC_0015591 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.6 | 77 | female | 3 | 51 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:36:01.338583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500204 | REC_0015592 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 12.5 | 69 | female | 0 | 24 | 5.8 | 7 | pembrolizumab 200 mg q3w | 11.9 | false | MSS | 2026-03-15T05:36:01.339071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837535 | REC_0015593 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 72 | female | 2 | 73 | 5.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:36:01.339479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737176 | REC_0015594 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 6.3 | 78 | male | 1 | 61 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 39.8 | true | MSS | 2026-03-15T05:36:01.339877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925247 | REC_0015595 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.6 | 69 | female | 0 | 22 | 5.7 | 5 | alectinib 600 mg BID | 7.8 | true | MSS | 2026-03-15T05:36:01.340574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434943 | REC_0015596 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 38 | 7.7 | 71 | female | 1 | 30 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.8 | true | MSS | 2026-03-15T05:36:01.341035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435524 | REC_0015597 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.6 | 90 | female | 2 | 8 | 3.5 | 5 | sotorasib 960 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:01.341422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770225 | REC_0015598 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 6.9 | 67 | female | 1 | 12 | 5.7 | 7 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:36:01.341796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820747 | REC_0015599 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 9.4 | 78 | male | 1 | 21 | 5.1 | 6 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:36:01.342190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514141 | REC_0015600 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.5 | 57 | male | 1 | 26 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:36:01.342627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.